TASLY* DE-TOXIN SHEET 4200MG/SHEET SHEET, LIGHT BROWN POWDER FORM

Indications

• Vitamin C deficiency
• Scurvy
• Adjunct therapy in iron overload conditions

Dosage

Children: Child 1 month–3 years: 125–250 mg daily in 1–2 divided doses; Child 4–11 years: 250–500 mg daily in 1–2 divided doses; Child 12–17 years: 0.5–1 g daily in 1–2 divided doses.

Adults: 500 mg daily, taken in 1-2 divided doses, depending on the clinical condition and dietary needs.

Mechanism of action

Ascorbic acid functions primarily as a reducing agent, facilitating enzymatic reactions in the body, including the hydroxylation of proline and lysine in collagen synthesis. It also plays a role in the absorption of iron from the gastrointestinal tract and enhances the immune response.

Pharmacodynamics

Ascorbic acid is crucial for the maintenance of connective tissue and is involved in the metabolism of several amino acids. Its antioxidant properties help to mitigate oxidative stress and may play a role in reducing the risk of chronic diseases.

Pharmacokinetics

Ascorbic acid is absorbed in the intestines and is widely distributed throughout the body. The renal clearance of ascorbic acid is dose-dependent, with higher doses leading to increased excretion. The half-life varies but is generally around 15 to 30 minutes in healthy individuals, with tissue saturation levels influencing its retention.

Contra-indications

• Hypercalcaemia
• Hyperoxaluria
• Patients with cardiac dysfunction

Adverse effects

• Abdominal pain
• Headache
• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Weight loss
• Polyuria
• Sweating
• Thirst
• Vertigo

Interactions

• Increases risk of cardiovascular adverse effects with iron chelators
• Increases risk of cardiovascular adverse effects with deferiprone
• Increases risk of cardiovascular adverse effects with desferrioxamine

Precautions

• Use with caution in patients with iron overload
• Monitor for symptoms of overdose

Pregnancy

High doses teratogenic in animals but therapeutic doses unlikely to be harmful.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Ascorbic acid 50 mg tablets
• Ascorbic acid 100 mg tablets
• Ascorbic acid 200 mg tablets
• Ascorbic acid 250 mg tablets
• Ascorbic acid 500 mg capsules

Indications

• Respiratory conditions
• Inflammation
• Digestive disorders
• Antioxidant support

Dosage

Children: There are no established paediatric dosages for bamboo or its extracts. It is recommended to consult a healthcare professional for advice tailored to individual circumstances.

Adults: There are no established adult dosages for bamboo or its extracts, as use varies widely depending on the form and intended purpose. It is advisable to refer to specific product guidelines or consult a healthcare professional.

Mechanism of action

The exact mechanism of action for bamboo, particularly its shoots, is not well-defined in conventional pharmacology. However, bamboo extracts have been shown to possess antioxidant properties, which can help reduce oxidative stress in the body. Some studies suggest that compounds found in bamboo may exert anti-inflammatory effects, potentially through the inhibition of pro-inflammatory cytokines and enzymes.

Pharmacodynamics

Bamboo shoots contain several bioactive compounds, including flavonoids, phenolic acids, and polysaccharides. These compounds contribute to the antioxidant and anti-inflammatory properties of bamboo. The antioxidant activity may help protect cells from damage caused by free radicals, while anti-inflammatory effects can aid in reducing swelling and discomfort associated with conditions such as arthritis.

Pharmacokinetics

The pharmacokinetics of bamboo and its extracts have not been extensively studied. However, it is known that the bioactive compounds in bamboo can be absorbed in the gastrointestinal tract after consumption. The metabolism of these compounds may occur in the liver, and they can potentially exert systemic effects through circulation. The elimination half-life and specific metabolic pathways remain largely undetermined.

Pregnancy

Limited information is available regarding the safety of bamboo during pregnancy. It is advisable to consult a healthcare provider.

Breast-feeding

Insufficient data exist on the excretion of bamboo components in human milk. Caution is recommended when using bamboo while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Weight management
• Reduction of cholesterol levels
• Support in dietary fat absorption

Dosage

Children: Refer to specific product guidelines as pediatric dosages are not well established.

Adults: Refer to specific product guidelines as dosages may vary widely based on formulation and concentration.

Mechanism of action

Chitosan acts primarily through its ability to bind dietary fats and cholesterol in the gastrointestinal tract, forming a complex that is not absorbed by the body. This mechanism reduces the absorption of fats and can lead to decreased calorie intake. Additionally, it may influence lipid metabolism and promote fat excretion.

Pharmacodynamics

Chitosan exhibits a high degree of biocompatibility and is non-toxic, which allows it to be safely ingested. Its lipid-binding properties contribute to a reduction in serum cholesterol levels and may help in weight management. The effects on lipid profiles are attributed to its ability to inhibit the absorption of dietary lipids and cholesterol.

Pharmacokinetics

Chitosan is not absorbed through the gastrointestinal tract due to its high molecular weight and polymeric structure. It passes through the digestive system largely unchanged. The effects of chitosan are primarily localized to the gut, where it interacts with dietary fats and cholesterol. Its elimination is through fecal excretion.

Adverse effects

• Gastrointestinal discomfort
• Nausea
• Constipation
• Diarrhea
• Flatulence

Precautions

• Use with caution in individuals with shellfish allergies, as chitosan is derived from chitin found in shellfish.
• Monitor for gastrointestinal side effects, particularly in patients with pre-existing digestive disorders.

Pregnancy

Chitosan is generally considered safe in pregnancy, but its effects have not been extensively studied. Consultation with a healthcare provider is recommended.

Breast-feeding

Chitosan is likely safe during breastfeeding, but limited data are available. Consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Formulations

• Capsules
• Tablets
• Powder

Dosage

Children: Refer to specific guidelines for pediatric dosing as it varies significantly based on the exact drug classification and clinical scenario.

Adults: Refer to specific guidelines for dosing as it varies significantly based on the exact drug classification and clinical scenario.

Mechanism of action

The mechanism of action of compounds referred to as doku may vary widely. Generally, such agents could act through modulation of neurotransmitter systems, inhibition of specific enzymes, or interaction with ion channels. For precise mechanisms, a specific compound must be identified.

Pharmacodynamics

Pharmacodynamics of doku-related agents may involve alterations in physiological responses through receptor binding or modulation of physiological pathways. The effects can be dose-dependent, with certain compounds exhibiting a threshold effect where lower doses may provide minimal therapeutic benefit while higher doses could lead to significant physiological changes.

Pharmacokinetics

Pharmacokinetics would depend on the specific compound under the doku classification, including absorption, distribution, metabolism, and excretion (ADME) profiles. Factors such as bioavailability, half-life, and routes of elimination are crucial but cannot be specified without identifying the exact drug.

Pregnancy

The safety of doku during pregnancy has not been well-established. It is recommended to avoid use unless the benefits outweigh the risks.

Breast-feeding

Doku may pass into breast milk. Caution is advised when administering to breastfeeding mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Culinary uses
• Food preservation
• Potential antimicrobial applications
• Dietary supplement for blood glucose management

Dosage

Children: Refer to specific dietary guidelines or culinary applications as there is no standardized clinical dosing for vinegar.

Adults: Refer to specific dietary guidelines or culinary applications as there is no standardized clinical dosing for vinegar.

Mechanism of action

Acetic acid induces apoptosis in yeast cells through mechanisms that involve alterations in the target of rapamycin (TOR) pathway. This pathway is crucial for various cellular processes, including amino-acid biosynthesis, carbohydrate metabolism, and stress response. The apoptotic signaling triggered by acetic acid involves the general amino-acid control (GAAC) system, indicating that acetic acid affects protein turnover and cell cycle regulation by modulating specific protein levels and pathways.

Pharmacodynamics

The pharmacodynamics of acetic acid suggest that it influences various metabolic pathways, particularly those related to amino-acid biosynthesis and stress responses. Its ability to induce apoptosis in yeast indicates a potential for modulating cell growth and death, although the clinical significance of these effects in humans remains unclear. It may also exhibit antimicrobial activity, contributing to its use as a preservative.

Pharmacokinetics

The pharmacokinetics of acetic acid are not extensively documented in the context of clinical use. However, when ingested, acetic acid is rapidly absorbed in the gastrointestinal tract. It is metabolized primarily in the liver and may influence the metabolism of carbohydrates and fats. Due to its acidic nature, acetic acid can affect gastric pH and subsequently influence the absorption of other substances.

Pregnancy

There is insufficient data on the use of vinegar during pregnancy. Caution is advised.

Breast-feeding

Limited data exists on the effects of vinegar during breastfeeding. Consult a healthcare professional before use.

Storage

Store in a cool, dark place, tightly sealed to maintain quality.

Formulations

• Vinegar (acetic acid solution)
• Apple cider vinegar
• White vinegar
• Balsamic vinegar

Mechanism of action

Although acetic acid has been shown to induce apoptosis in yeast, the exact apoptotic mechanisms remain unknown. Here, /the study examined/ the effects of acetic acid treatment on yeast cells by 2-DE, revealing alterations in the levels of proteins directly or indirectly linked with the target of rapamycin (TOR) pathway: amino-acid biosynthesis, transcription/translation machinery, carbohydrate metabolism, nucleotide biosynthesis, stress response, protein turnover and cell cycle. The increased levels of proteins involved in amino-acid biosynthesis presented a counteracting response to a severe intracellular amino-acid starvation induced by acetic acid. Deletion of GCN4 and GCN2 encoding key players of general amino-acid control (GAAC) system caused a higher resistance to acetic acid indicating an involvement of Gcn4p/Gcn2p in the apoptotic signaling. Involvement of the TOR pathway in acetic acid-induced apoptosis was also reflected by the higher survival rates associated to a terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-negative phenotype and lower reactive oxygen species levels of Deltator1 cells. In addition, deletion mutants for several downstream mediators of the TOR pathway revealed that apoptotic signaling involves the phosphatases Pph21p and Pph22p but not Sit4p. Altogether, /these/ results indicate that GAAC and TOR pathways (Tor1p) are involved in the signaling of acetic acid-induced apoptosis. Acetic acid was found to have actions on urinary bladder smooth muscle in /the/ routine ion channel screening assays. Numerous studies have examined the mechanisms of bladder irritation by acetic acid; however, the direct effect of acetic acid on ion channels in detrusor smooth muscle cells has not been evaluated. /The study/ used whole-cell patch-clamp techniques to examine the effect of acetic acid on large-conductance Ca2+-activated K+ channels (BKCa) from guinea pig detrusor smooth muscle cells and CHO cells expressing recombinant human BKCaalphabeta1 (CHO BKCaalphabeta1) and human BKCaalpha (CHO BKCaalpha). Acetic acid activated BKCa currents in a concentration-dependent (0.01% to 0.05% v/v) manner in all the cell systems studied. Acetic acid (0.05%) increased BKCa current at +30 mV by 2764 +/- 918% (n=8) in guinea pig detrusor smooth muscle cells. Acetic acid (0.03%) shifted the V1/2 of conductance-voltage curve by 64 +/- 14 (n=5), 128 +/- 14 (n=5), and 126 +/- 12 mV (n=4) in CHO BKCaalpha, CHO BKCaalphabeta1 and detrusor smooth muscle cells, respectively. This effect of acetic acid was found to be independent of pH and was also not produced by its salt form, sodium acetate. Automated patch-clamp experiments also showed similar activation of CHO BKCaalphabeta1 by acetic acid. In conclusion, acetic acid directly activates BKCa channels in detrusor smooth muscle cells. This novel study necessitates caution while interpreting the results from acetic acid bladder irritation model. /It was/ previously shown that acetic acid activates a mitochondria-dependent death process in Saccharomyces cerevisiae and that the ADP/ATP carrier (AAC) is required for mitochondrial outer membrane permeabilization and cytochrome c release. Mitochondrial fragmentation and degradation have also been shown in response to this death stimulus. Herein, /the study/ show that autophagy is not active in cells undergoing acetic acid-induced apoptosis and is therefore not responsible for mitochondrial degradation. Furthermore, /the study/ found that the vacuolar protease Pep4p and the AAC proteins have a role in mitochondrial degradation using yeast genetic approaches. Depletion and overexpression of Pep4p, an orthologue of human cathepsin D, delays and enhances mitochondrial degradation respectively. Moreover, Pep4p is released from the vacuole into the cytosol in response to acetic acid treatment. AAC-deleted cells also show a decrease in mitochondrial degradation in response to acetic acid and are not defective in Pep4p